Rajpurohit R, Lee S O, Park J O, Paik W K, Kim S
Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
J Biol Chem. 1994 Jan 14;269(2):1075-82.
We have previously reported the existence of two different molecular species of protein methylase I (S-adenosylmethionine:protein-arginine N-methyltransferase, E.C. 2.1.1.23) in calf brain, one specific for myelin basic protein and the other for histone (Ghosh, S. K., Paik, W. K., and Kim, S. (1988) J. Biol. Chem. 263, 19024-19033). In the present study, however, we report that heterogeneous ribonucleoprotein particle protein A1 is most likely an in vivo substrate for the "histone-specific protein methylase I." The unmethylated recombinant protein A1 has been found to be a much superior methyl acceptor for the enzyme than histone with a Km value two orders of magnitude lower (0.19 microM) than that for histone (21 microM). Myelin basic protein, a specific inhibitor for histone protein methylase I, exhibited a lower IC50 for protein A1 methylation (IC50 = 33 microM) compared with histone methylation (IC50 = 220 microM) and competitively inhibited the former with a Ki value of 1.3 x 10(-6) M. The extent of inhibition of protein A1 and histone methylation by the polyclonal antibodies prepared against purified "histone protein methylase I" was identical. Maximally, 1.08-mol methyl groups were incorporated per mol of protein A1, which was 27-fold higher than that of histone (0.04 mol/mol of histone). HPLC analysis of the enzymatically methylated amino acid residues in protein A1 revealed the formation of NG-monomethylarginine and NG,NG-dimethylarginine. The ratio of NG,NG-dimethylarginine/NG-monomethylarginine increased as a function of incubation period; however, NG,N'G-dimethylarginine was not detectable. Proteolytic cleavage of the methyl-3H-labeled recombinant protein A1 by trypsin and Staphylococcus aureus V8 endoprotease indicated that protein A1 possesses multiple sites for methylation, one of which was identified as residue 194 arginine, which coincided with the in vivo methylation site.
我们之前报道过在小牛脑中存在两种不同分子形式的蛋白甲基化酶I(S-腺苷甲硫氨酸:蛋白精氨酸N-甲基转移酶,E.C. 2.1.1.23),一种对髓鞘碱性蛋白具有特异性,另一种对组蛋白具有特异性(戈什,S.K.,派克,W.K.,和金,S.(1988年)《生物化学杂志》263,19024 - 19033)。然而,在本研究中,我们报道异质性核糖核蛋白颗粒蛋白A1很可能是“组蛋白特异性蛋白甲基化酶I”的体内底物。已发现未甲基化的重组蛋白A1作为该酶的甲基受体比组蛋白优越得多,其Km值比组蛋白的Km值(21 microM)低两个数量级(0.19 microM)。髓鞘碱性蛋白是组蛋白蛋白甲基化酶I的特异性抑制剂,与组蛋白甲基化(IC50 = 220 microM)相比,其对蛋白A1甲基化的IC50较低(IC50 = 33 microM),并以1.3×10^(-6) M的Ki值竞争性抑制前者。针对纯化的“组蛋白蛋白甲基化酶I”制备的多克隆抗体对蛋白A1和组蛋白甲基化的抑制程度相同。每摩尔蛋白A1最多可掺入1.08摩尔甲基,这比组蛋白(每摩尔组蛋白0.04摩尔)高27倍。对蛋白A1中酶促甲基化氨基酸残基的HPLC分析显示形成了NG-单甲基精氨酸和NG,NG-二甲基精氨酸。NG,NG-二甲基精氨酸/NG-单甲基精氨酸的比例随孵育时间增加而增加;然而,未检测到NG,N'G-二甲基精氨酸。用胰蛋白酶和金黄色葡萄球菌V8内切蛋白酶对甲基-3H标记的重组蛋白A1进行蛋白水解切割表明,蛋白A1具有多个甲基化位点,其中一个被鉴定为第194位精氨酸残基,这与体内甲基化位点一致。